Enterococci are among the common organisms associated with hospital-acquired infections. We examined in vitro activities of different antibiotics to 103 enterococcal isolates. Minimal inhibitory concentrations (MICs) of penicillin G, ampicillin, gentamicin, ciprofloxacin, ofloxacin, levofloxacin, grepafloxacin, trovafloxacin and gemifloxacin were determined by broth microdilution testing method. Among the isolates 71 (69%) were identified as E. faecalis and 32 (31%) as E. faecium. While over 75% of E. faecium isolates were resistant to penicillin and ampicillin, approximately 25% of E. faecalis isolates were resistant to penicillin and ampicillin. None of the E. faecalis and E. faecium isolates were resistant to vancomycin. While 17 (52%) of E. faecium isolates exhibited high-level gentamicin resistance (HLGR), high level streptomycin resistance (HLSR) was detected in 24 (74%) of the isolates. In contrast, HLGR and HLSR rates for E. faecalis were 14 (20%) and 22 (31%), respectively. Both HLGR and HLSR were detected with higher frequency in ampicillin resistant isolates. Among fluoroquinolones, gemifloxacin and trovafloxacin were the most potent antibiotics tested. There was no increase in MIC 90 values of the fluoroquinolones in ampicillin resistant isolates in comparison with ampicillin susceptible isolates. Our data suggest newer fluoroquinolones would be good alternative agents to use especially for combination drug therapy where enterococci with ampicillin resistance and HLAR are prevalent.
Enterococci are the fourth most common organisms associated with hospital-acquired infection, representing 10% of isolates (Kaye et al. 2000) . Enterococci are common causes of nosocomial urinary tract infections, surgical site infections, and bloodstream infections, representing 16%, 12%, and 9% of isolates, respectively (Kaye et al. 2000) . The emergence of enterococci as significant pathogens is a matter of concern because these organisms are inherently resistant to a number of antimicrobial agents. Enterococci acquired high-level resistance to aminoglycosides (Bingen et al. 1991; Huycke et al. 1998) followed by emergence of ampicillin-resistant enterococci. Eventually vancomycin-resistant enterococci (VRE) emerged (Leclercq et al. 1988; Sapico et al. 1989; Murray et al. 1991) . Increasing antimicrobial resistance has dictated the development of new antibiotics such as the fluoroquinolones which may potentially offer activity. In this study, we examined in vitro activities of different antibiotics to 103 enterococcal isolates collected in the hospital of Istanbul Medical Faculty.
MATERIALS AND METHODS
In total, 103 clinical isolates of Enterococcus spp. (derived from bloodstream infection, urinary tract infection, surgical site infection and central nervous system infection between January 2000 and December 2001) were analyzed. Isolates were identified to the genus and species level by standard biochemical tests (Facklam and Collins 1989; Facklam and Sahm 1995) as well as a commercially available kit (API 20 Strep, bioMerieux, Marcy l'Etoie, France). Minimal inhibitory concentrations (MICs) of penicillin G, ampicillin, gentamicin, ciprofloxacin, ofloxacin, levofloxacin, grepafloxacin, trovafloxacin and gemifloxacin were determined by the NCCLS recommended broth microdilution testing method (NCCLS, 2000) . Microdilution panels used in this study (MicroScan ® , Dade International Inc., West Sacramento, CA, USA) were kindly provided by SmithKline Beecham, Turkey. Enterococcus faecalis ATCC 49212 was used as control strain. MIC of vancomycin was determined by the E-test (AB Biodisk, Solna, Sweden) on Brain-Heart Infusion agar (Oxoid, Hampshire, England) (Schulz and Sahm 1993) . High-level disks of 120 µg gentamicin (Oxoid, Hampshire, England) and 300 µg streptomycin (Oxoid, Hampshire, England) were used to screen for high-level aminoglycoside resistance (HLAR) (NCCLS, 2000) . Production of -lactamase was tested with nitrocefin-based -lactamase test (Oxoid, Hampshire, England) (NCCLS 2000) .
RESULTS
Among the 103 enterococcal strains 71 (69%) were identified as E. faecalis and 32 (31%) as E. faecium. Results of the in vitro activities of antimicrobial agents against E. faecalis and E. faecium isolates are shown in Table 1 . While over 75% of E. faecium isolates were resistant to penicillin and ampicillin, approximately 25% of E. faecalis isolates were resistant to penicillin and ampicillin. The penicillin-resistant strains were negative for -lactamase production. None of the E. faecalis and E. faecium isolates were resistant to vancomycin. While 17 (52%) of E. faecium isolates exhibited high-level gentamicin resistance (HLGR), high-level streptomycin resistance (HLSR) was detected in 24 (74%) of the isolates. In contrast, 14 (20%) and 22 (31%) of E. faecalis isolates exhibited HLGR and HLSR, respectively (Table 2) .
Gemifloxacin and trovafloxacin were the most potent antibiotics tested for E. faecalis and E. faecium isolates (MIC 90 =4 mg/liter) among the fluoroquinolones. They were followed by grepafloxacin, levofloxacin, ciprofloxacin and ofloxacin ( dilution lower for ampicillin-resistant isolates (Table 4) .
DISCUSSION
Enterococci are increasingly recognised as important causes of hospital infections (Murray 2000) . The growing incidence of enterococcal infections is a great concern due to multi-drug resistance resulting from intrinsic and easily acquired mechanisms (Facklam and Collins 1989; Baron et al. 1995; Murray 2000) .
E. faecalis was the species more frequently isolated from all clinical samples as reported in previous studies (Murray 1990; Guiney and Urwin 1993; Facklam and Sahm 1995; Pangon et al. 1999) . The finding that approximately 25% of E. faecalis isolates and over 75% of E. faecium isolates were resistant to penicillin and ampicillin has great importance, since penicillin and ampicillin are the main drugs in the treatment of enterococcal infections (Murray 2000) .
Penicillin resistance in E. faecalis that is mediated by -lactamase production has been reported from few nosocomial outbreaks (Murray et al. 1991; Murray 1992) . In general, however, -lactam resistance among enterococci is centered in E. faecium, where it is associated with production of a low-affinity penicillinbinding protein, PBP-5, and not with -lactamase (Livermore 1995) . In our study -lactamase activity was not detected in Enterococcus spp. isolates of which penicillin and ampicillin MICs were > 16 mg/liter.
The increase in glycopeptide resistance followed the marked increase in vancomycin usage in many hospitals, as methicillin-resistant Staphylococcus aureus (MRSA) strains became established in 1980s. The vast majority of VRE appear to have been acquired nosocomially or institutionally, and spread of epidemic strains both within and between institutions is welldocumented (Livornese et al. 1992) . From 1989 to 1998, the proportion of enterococcal isolates from intensive care units (ICUs) that were resistant to vancomycin increased from 0.3% to 23.9% (Kaye et al. 2000) . Although risk factors for VRE infections such as exposure to broad spectrum cephalosporins, vancomycin and antimicrobial agents with significant anaerobic activity, longer length of hospital stays, use of enteral tube feedings or sucralfate (Pallares et al. 1993; Edmond et al. 1995; Tornieporth et al. 1996) are very common in our hospital, none of the isolates in this study were resistant to vancomycin.
Generally, enteroccocal infections are treated with combination therapies and HLAR is a great concern, since it eliminates synergy with cellwall active antibiotics (Krogstad et al. 1978) . Our present data indicate the significant frequency of strains with HLAR phenotypes. HLSR was detected more frequently than HLGR in both E. faecalis and E. faecium isolates. Most of the E. faecium isolates exhibited HLGR (52%) and HLSR (74%). Over 43% of isolates were resistant to both antibiotics. This HLAR phenotype was also common among E. faecalis isolates with resistance to streptomycin (31%) and gentamicin (20%). The high frequency of HLAR points to the alternative agents such as fluoroquinolones which may be used in combination with penicillin or ampicillin for enterococcal infections especially in endocarditis (Sacher et al. 1991; Rambaldi et al. 1997; Tripodi et al. 1998) . HLAR was detected at least two-fold more frequently in ampicillin resistant isolates than in ampicillinsusceptible isolates. This suggests that alternative antibiotics should be used for the treatment of enterococcal infections especially when ampicillin resistant strains are prevalent.
Over the last decade, the fluoroquinolones have become a dominant class of antimicrobial agents. No other class of antimicrobial agents has grown so rapidly or been developed with such interest by pharmaceutical research companies. One of the aims of this study was to assess the antibiotic resistance of clinical isolates of enterococci to several fluoroquinolone compounds. The study demonstrates the newer fluoroquinolones have good in vitro activities against clinical Enterococcus spp. isolates. The results show that gemifloxacin and trovafloxacin are the most active of the fluoroquinolones tested followed by grepafloxacin, levofloxacin, ciprofloxacin and ofloxacin. Althoughlactams and aminoglycosides are traditional therapeutic agents for enterococci, because of resistance patterns emerging, alternative therapies are increasingly being considered. In this regard, we compared the susceptibility of the fluoroquinolones in ampicillin-susceptible and ampicillin-resistant enterococcal groups. There was no increase in MIC 90 values of the quinolones between these two groups. One of the goals of our study was to evaluate the activities of newer fluoroquinolones against vancomycin resistant isolates, which actually stand as a danger for human life, since some resistant isolates were recently reported from Turkey (Basustaoglu et al. 2001; Colak et al. 2002) . As a relatively small number of isolates were tested and all of the isolates were susceptible to vancomycin, the conclusions in this regard are limited. However, our data suggest newer quinolones would be good alternative agents to use especially for combination drug therapy in communities or hospitals where enterococci with ampicillin resistance and HLAR are prevalent. Fluoroquinolones should also be considered alternatives for patients for whom first line antibiotics can not be used because of resistance patterns or side affects. Enterococci often cause mixed infections in hospital setting and fluoroquinolones are widely used for nosocomial infections empirically. This could also be a factor in choosing fluoroquinolones. Enterococcal infections are inherently resistant to therapy and newer fluoroquinolones should be tested clinically to show whether in vitro activity predicts in vivo activity too.
